BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 25979341)

  • 1. The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
    Yang Y; Blair HC; Shapiro IM; Wang B
    J Biol Chem; 2015 Jul; 290(27):16918-28. PubMed ID: 25979341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
    Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
    Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
    Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
    Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
    Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.
    Singh K; Piprode V; Mhaske ST; Barhanpurkar-Naik A; Wani MR
    J Immunol; 2018 Jan; 200(2):595-606. PubMed ID: 29203513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
    Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
    Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
    Ang E; Pavlos NJ; Rea SL; Qi M; Chai T; Walsh JP; Ratajczak T; Zheng MH; Xu J
    J Cell Physiol; 2009 Aug; 220(2):450-9. PubMed ID: 19365810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establish mouse osteoblast -osteoclast cell co-culture system in a Transwell chamber].
    Mo GY; Zhang SC; Li YX; Guo HZ; Guo DQ; Li DX; Tang YC; Mo L; Luo PJ; Ma YH
    Zhongguo Gu Shang; 2018 Mar; 31(3):241-247. PubMed ID: 29600675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.
    Choudhary S; Goetjen A; Estus T; Jacome-Galarza CE; Aguila HL; Lorenzo J; Pilbeam C
    J Biol Chem; 2016 Feb; 291(8):3882-94. PubMed ID: 26703472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.